Stifel has initiated coverage of Transmedics Group Inc (TMDX), assigning a Hold rating. This marks the firm's first assessment of the company's investment potential, reflecting its research into the business, industry dynamics, and growth prospects.
Transmedics Group operates as a commercial stage medical technology company, headquartered in Andover, Massachusetts. The firm employs 728 full-time staff and specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its flagship product, the Organ Care System (OCS), is designed to replicate near-physiologic conditions for donor organs outside the human body. Additionally, the company has developed the National OCS Program (NOP), a comprehensive solution that includes organ procurement, OCS perfusion management, and transplant logistics services.
As of September 3, 2025, Transmedics Group's stock is priced at $129.79. The company has a market capitalization of $4.2 billion and a price-to-earnings ratio (P/E) of 46.19, with an earnings per share (EPS) of 2.29. Upcoming earnings are anticipated on July 28, 2026, with an estimated EPS of $0.81 and revenue of $189.2 million.
Analyst ratings are subject to change as new information becomes available. Currently, the consensus among analysts is a Buy, with 7 Strong Buy, 8 Buy, 4 Hold, and no Sell or Strong Sell ratings recorded as of November 1, 2025.